Skip to main content

Bailey John E. (Jack) Jr.'s Form 4 filing

G1 Therapeutics, Inc. (GTHX) · filed Jan 5, 2022

Accession no.
0001562180-22-000302
Filed
Jan 5, 2022
Trade date
Jan 3, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $355.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bailey John E. (Jack) Jr.CIK 0001806147Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 3, 2022Common StockAGrant or awardAcquired+46,000$0.00F2$0267,333Direct
Jan 3, 2022Common StockSSaleDisposed−34,125$10.41F5−$355,241.25233,208Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 3, 2022Common StockAGrant or awardAcquired+204,000$0.00$0204,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Each RSU represents a contingent right to receive one share of Issuer common stock.

Referenced by the price of 1 transaction in Table I.

F5

The price represents the weighted average price with a low of $10.16 and a high of $10.67. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)